Targeting senescence as an anti-cancer therapy
File(s)
Author(s)
Bousset, Laura
Gil, Jesús
Type
Journal Article
Abstract
Cellular senescence is a stress response elicited by different molecular insults. Senescence results in cell cycle exit and is characterised by multiple phenotypic changes such as the production of a bioactive secretome. Senescent cells accumulate during ageing and are present in cancerous and fibrotic lesions. Drugs that selectively kill senescent cells (senolytics) have shown great promise for the treatment of age-related diseases. Senescence plays paradoxical roles in cancer. Induction of senescence limits cancer progression and contributes to therapy success, but lingering senescent cells fuel progression, recurrence, and metastasis. In this review, we describe the intricate relation between senescence and cancer. Moreover, we enumerate how current anti-cancer therapies induce senescence in tumour cells and how senolytic agents could be deployed to complement anticancer therapies. "One-two punch" therapies aim to first induce senescence in the tumour followed by senolytic treatment to target newly exposed vulnerabilities in senescent tumour cells. "One-two punch" represents an emerging and promising new strategy in cancer treatment. Future challenges of "one -two punch" approaches include how to best monitor senescence in cancer patients to effectively survey their efficacy.
Date Issued
2022-11
Date Acceptance
2022-08-21
Citation
Molecular Oncology, 2022, 16 (21), pp.3855-3880
ISSN
1574-7891
Publisher
Wiley Open Access
Start Page
3855
End Page
3880
Journal / Book Title
Molecular Oncology
Volume
16
Issue
21
Copyright Statement
© 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/36065138
Subjects
Cellular senescence
chemotherapy
oncogene-induced senescence (OIS)
radiotherapy
senolytics
therapy-induced senescence (TIS)
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2022-09-05